Assessing Effects of BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym®

Diane M. Longo¹, Lisl K. M. Shoda¹, Brett A. Howell¹, Vladimir Coric², Robert M. Berman², Irfan A. Qureshi²

¹DILIsym Services, Inc., Research Triangle Park, NC; ²Biohaven Pharmaceuticals, Inc., New Haven, CT, USA

1. Premise

- Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the death of motor neurons that leads to progressive muscle weakness and difficulties in speaking, swallowing, and breathing.
- Riluzole prolongs survival and time to tracheostomy in patients with ALS.
- Because of its sublingual route of administration, BHV-0223 bypasses first-pass metabolism, achieving adequate drug concentrations with diminished drug burden and potentially less risk of liver toxicity.
- This study quantitatively and mechanistically compared liver toxicity potential of oral riluzole versus BHV-0223, combining clinical and mechanistic data, using DILIsym®.

2. Methods

- DILIsym is a validated multi-scale computational model that supports evaluation of liver toxicity risks.
- Oral riluzole (50 mg twice daily [BID] for 12 weeks) and sublingual riluzole (40 mg BID for 12 weeks) were simulated by combining a physiologically-based pharmacokinetic (PBPK) modelling representation of riluzole with mechanistic liver toxicity parameters derived from in vitro data.
- The DILIsym PBPK model framework used for riluzole consists of a compartmental model of the body with compartments for blood, gut, liver, muscle, and other tissues (Figure 1).

3. Results

- DILIsym simulations reasonably captured the plasma PK of riluzole (Figure 2).
- PK data were used to estimate the portion of sublingual riluzole that is absorbed via the oral mucosa and the portion that is swallowed and passes through the gastrointestinal (GI) tract. Simulated plasma concentrations after a sublingual dose were conducted, assuming a variable fraction of the dose is absorbed via the oral mucosa.
- Simulations in which 0% of a sublingual dose of riluzole was absorbed via the oral mucosa and 100% passed through the GI tract underestimated observed plasma concentrations.

4. Conclusions

- While both deliver bioequivalent exposures, sublingual BHV-0223 theoretically has less risk of liver toxicity compared to riluzole oral tablets. DILIsym modeling demonstrated that sublingual BHV-0223 confers diminished rates of liver toxicity compared to oral tablets of riluzole, consistent with having a lower overall dose of riluzole and bypassing first-pass liver metabolism.
- Key determinants of the simulated outcomes included liver exposure relative to plasma. Physiologically reasonable assumptions regarding liver exposure confirmed the propensity for oral riluzole tablets to confer elevations in liver function tests at rates that are comparable to that observed clinically, thus validating the DILIsym representation of oral riluzole.